Immunogen Inc
IMGN
IMGN was delisted on the 9th of February, 2024.
200 hedge funds and large institutions have $666M invested in Immunogen Inc in 2017 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 64 increasing their positions, 52 reducing their positions, and 29 closing their positions.
77% more call options, than puts
Call options by funds: $3.45M | Put options by funds: $1.94M
72% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 29
23% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 52
11% more funds holding
Funds holding: 180 → 200 (+20)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $691M → $666M (-$24.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$18.5M |
| 2 |
Morgan Stanley
New York
|
+$17.9M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$17.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$16.1M |
| 2 |
Millennium Management
New York
|
-$5.22M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$4.52M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.41M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$3.43M |
IMGN Hedge Fund Activity: Q4 2017 in Review
200 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q4 2017, worth a combined $666M — down 3.5% from $691M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new IMGN positions and 29 closed out — a net gain of 21 holders — while 64 added to existing stakes and 52 trimmed.
The largest buyer was BlackRock, adding an estimated $18.5M. The largest seller was OrbiMed, cutting an estimated $16.1M.
- 200 institutional investors held Immunogen Inc (IMGN) as of Q4 2017, up from 180 in Q3 2017.
- Funds reported $666M of Immunogen Inc stock for Q4 2017, down 3.5% quarter-over-quarter.
- 50 funds opened new Immunogen Inc positions in Q4 2017 and 29 closed out, a net change of +21 holders.
- The largest Immunogen Inc buyer in Q4 2017 was BlackRock, an estimated $18.5M added.
- The largest Immunogen Inc seller in Q4 2017 was OrbiMed, an estimated $16.1M sold.
Based on aggregated 13F filings for Q4 2017.